Novel Rx

Inhibition of B-cell Activating Factor (BAFF) has revolutionised the treatment of patients with systemic lupus erythematosus (SLE). However, outcomes of therapies within the same class (i.e. BAFF-…

The RheumNow faculty reporters have been scouring the meeting and online presentations to find the best abstracts from ACR22. Here are some of their choice abstracts reported today on day 1 of…

The management of rheumatoid arthritis patients with a history of cancer continues to be an area of concern for rheumatologists. General recommendations are to treat patients with a history of solid…

Adult Still's Disease is labeled as a rare disease as the prevalence of the disease is low –  in some reports it is as low as 0.16 per 100,000 population. Adult Still’s disease constitutes Adult…

Type I interferon (IFN) is a powerful immune activator that is present at high levels in the majority of patients with lupus, an autoimmune disease. In Arthritis & Rheumatology, researchers…

Rheumatoid arthritis treatment has come leaps and bounds in recent decades. Gone are the days of gold injections, chemical synovectomies, and physician-mandated bedrest (heaven forbid). Though the…

The updated 2022 EULAR recommendations for the management of rheumatoid arthritis (RA) were initially presented by Dr. Josef Smolen at EULAR 2022, and are now in press delineating the most recent…

As we approach ACR22, there are many things to be excited about, especially with the reintroduction of in-person attendance. There are three areas that always draw my attention each conference and…

Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic musculoskeletal disease which can be managed with both pharmacological and non-pharmacological options. The joint ASAS-EULAR…